When Dr. Jun Kang's team at Johns Hopkins Medicine set out to study hydroxychloroquine in discoid lupus patients, they challenged a long-standing assumption: that skin lupus was merely a skin problem. What they found could reshape how doctors treat the condition, particularly for the young to middle-aged Black women who bear the highest burden of this disfiguring disease.
Discoid lupus erythematosus—a form of skin lupus that causes disk-shaped plaques across the body—has historically been treated as a cosmetic concern, addressed with topical creams and the occasional oral corticosteroid. But newer research, including Kang's own work, has revealed something more troubling: the condition is linked to systemic inflammation and heart disease risk that mirrors systemic lupus erythematosus, a far more serious autoimmune condition. This insight opened a crucial question: could hydroxychloroquine, a drug long used to manage systemic lupus, also protect patients with skin-only lupus from cardiovascular and metabolic complications?
The study, published in the Journal of the American Academy of Dermatology, examined two separate patient populations over five years. The first cohort included 106 adults from Johns Hopkins Medicine clinics (67% Black, 26.4% white, 6.6% Asian), with a mean age of 47.8 years. Among them, 60 were actively taking hydroxychloroquine while 46 had never taken the drug. A second, much larger cohort drawn from TriNetX, a database of deidentified patient records, included 4,520 participants matched for key characteristics—half taking hydroxychloroquine and half serving as controls.
The results were striking. Among Johns Hopkins patients, those taking hydroxychloroquine were far less likely to develop hyperlipidemia (elevated cholesterol), with rates of 23.3% compared to 47.8% in the untreated group—a 51% relative risk reduction. Coronary artery disease risk dropped from 26.1% to 10.0%, a 61% reduction. Patients on the drug also showed dramatically lower rates of peripheral artery disease (1.7% vs. 17.4%) and angina, or chest pain (3.3% vs. 26.1%).
The TriNetX cohort, though showing smaller absolute differences, confirmed the pattern across a much larger and more diverse population. Hydroxychloroquine users had lower rates of hypertension, type 2 diabetes, stroke, and coronary artery disease. Interestingly, neither group showed significant differences in heart attack or stroke risk at Johns Hopkins, suggesting the drug may protect against specific cardiovascular pathways rather than serving as a blanket prevention tool.
"Our study found that hydroxychloroquine use was associated with better cardiovascular and cardiometabolic health outcomes, including diabetes, in patients after five years," Kang said. The finding is particularly significant because it suggests that systemic therapies—drugs designed to calm the immune system broadly—may offer benefits beyond treating surface symptoms.
The research marks a subtle but important shift in how lupus specialists think about skin disease. Instead of asking "Will this reduce plaques?" doctors may now ask "Will this protect the heart and metabolism?" The team's next goal is to identify which discoid lupus patients would benefit most from hydroxychloroquine as a first-line treatment, potentially leading to new clinical guidelines that could spare thousands from preventable complications.